https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-nucala-mepolizumab-for-the-treatment-of-children-with-severe-asthma/
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma...
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
https://publikationen.uni-tuebingen.de/xmlui/handle/10900/163461
Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue,...
chronic rhinosinusitisnasal polypsmonitoringmepolizumabtreatment
https://visualping.io/pages/lap-of-mepolizumab-for-mea115921-participants-clinical-trial-alerts-4960320
LAP of Mepolizumab for MEA115921 Participants Clinical Trial: Get alerts for the latest updates -...
See the latest updates to LAP of Mepolizumab for MEA115921 Participants Clinical Trial. Subscribe for free to get alerts when changes are detected to LAP of...
https://www.iris.unicz.it/handle/20.500.12317/112286
Impact of Demographics on Mepolizumab Effectiveness in Severe Asthma: One-Year REALITI-A Subanalysis
https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-receives-positive-chmp-opinion-for-treatment-of-chronic-obstructive-pulmonary-disease/
Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary...
Nucala is the only monthly biologic studied in a wide COPD population with an eosinophilic phenotype.
https://gskpro.com/en-ie/products/nucala/home/?cc=prt:IE:nuc:NucalaLaunch:fa7un025:hcp:SevereAsthma:res:Print:Awareness:ViewContent
Nucala (mepolizumab)
Nucala (mepolizumab) information for Healthcare Professionals registered in Ireland.
nucalamepolizumab